Editorial: Advancing therapeutic strategies: exploring ABC transporters and chemicals affecting their expression and function for disease treatment.
作者信息
Veit Guido, Matsuo Michinori, Okiyoneda Tsukasa
机构信息
Department of Physiology, McGill University, Montréal, QC, Canada.
Department of Food and Nutrition, Faculty of Home Economics, Kyoto Women's University, Kyoto, Japan.
出版信息
Front Pharmacol. 2024 May 13;15:1423979. doi: 10.3389/fphar.2024.1423979. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Advancing therapeutic strategies: exploring ABC transporters and chemicals affecting their expression and function for disease treatment.社论：推进治疗策略：探索ABC转运蛋白及影响其表达和功能的化学物质用于疾病治疗
Front Pharmacol. 2024 May 13;15:1423979. doi: 10.3389/fphar.2024.1423979. eCollection 2024.
2
Positional effects of premature termination codons on the biochemical and biophysical properties of CFTR.提前终止密码子对 CFTR 的生化和物理特性的位置效应。
J Physiol. 2020 Feb;598(3):517-541. doi: 10.1113/JP278418. Epub 2019 Nov 2.
3
The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis.提前终止密码子突变对人鼻腔上皮和肠类器官中 CFTR mRNA 丰度的影响：囊性纤维化中通读治疗的基础。
Hum Mutat. 2019 Mar;40(3):326-334. doi: 10.1002/humu.23692. Epub 2018 Dec 10.
4
Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis.PTC 轴承 CFTR mRNA 的完整性和稳定性及其对囊性纤维化未来调节剂治疗的相关性。
Genes (Basel). 2021 Nov 18;12(11):1810. doi: 10.3390/genes12111810.
5
6
Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.合成氨基糖苷类药物能有效抑制囊性纤维化跨膜电导调节因子无义突变，并被依伐卡托增强。
Am J Respir Cell Mol Biol. 2014 Apr;50(4):805-16. doi: 10.1165/rcmb.2013-0282OC.
7
Mutating the Conserved Q-loop Glutamine 1291 Selectively Disrupts Adenylate Kinase-dependent Channel Gating of the ATP-binding Cassette (ABC) Adenylate Kinase Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Reduces Channel Function in Primary Human Airway Epithelia.突变保守的Q环谷氨酰胺1291会选择性破坏ATP结合盒（ABC）腺苷酸激酶囊性纤维化跨膜传导调节因子（CFTR）的腺苷酸激酶依赖性通道门控，并降低原代人呼吸道上皮细胞中的通道功能。
J Biol Chem. 2015 May 29;290(22):14140-53. doi: 10.1074/jbc.M114.611616. Epub 2015 Apr 17.
8
Evolutionary and functional divergence between the cystic fibrosis transmembrane conductance regulator and related ATP-binding cassette transporters.囊性纤维化跨膜传导调节因子与相关ATP结合盒转运蛋白之间的进化和功能差异。
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18865-70. doi: 10.1073/pnas.0806306105. Epub 2008 Nov 19.
9
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.用于治疗囊性纤维化的阿他芦醇及类似化合物（针对I类提前终止密码子突变的特定疗法）。
Cochrane Database Syst Rev. 2017 Jan 19;1(1):CD012040. doi: 10.1002/14651858.CD012040.pub2.
10
Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.肠类器官中 CFTR 无义突变的功能修复。
J Cyst Fibros. 2022 Mar;21(2):246-253. doi: 10.1016/j.jcf.2021.09.020. Epub 2021 Oct 17.
本文引用的文献
1
ABC transporters: human disease and pharmacotherapeutic potential.ABC转运蛋白：人类疾病与药物治疗潜力
Trends Mol Med. 2023 Feb;29(2):152-172. doi: 10.1016/j.molmed.2022.11.001. Epub 2022 Dec 8.
2
The human ATP-binding cassette (ABC) transporter superfamily.人类 ATP 结合盒（ABC）转运蛋白超家族。
Hum Mutat. 2022 Sep;43(9):1162-1182. doi: 10.1002/humu.24418. Epub 2022 Jun 22.
3
Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.炎性细胞因子 TNF-α 和 IL-17 增强囊性纤维化跨膜电导调节剂调节剂的疗效。
J Clin Invest. 2021 Aug 16;131(16). doi: 10.1172/JCI150398.
4
Airway Epithelial Inflammation Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies.气道上皮炎症增强了当前CFTR调节剂疗法对突变型CFTR的挽救作用。
Front Pharmacol. 2021 Mar 30;12:628722. doi: 10.3389/fphar.2021.628722. eCollection 2021.
5
Discovery of CFTR modulators for the treatment of cystic fibrosis.囊性纤维化治疗药物 CFTR 调节剂的发现。
Expert Opin Drug Discov. 2021 Aug;16(8):897-913. doi: 10.1080/17460441.2021.1912732. Epub 2021 Apr 13.
6
Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR.依利卓卡福特增强 F508del 和 CFTR 门控突变体的活性。
J Cyst Fibros. 2021 Sep;20(5):895-898. doi: 10.1016/j.jcf.2021.03.011. Epub 2021 Mar 26.
7
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
8
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
9
Functional rescue of misfolding ABCA3 mutations by small molecular correctors.小分子校正剂对 ABCA3 突变错误折叠的功能拯救。
Hum Mol Genet. 2018 Mar 15;27(6):943-953. doi: 10.1093/hmg/ddy011.
10
Targeted pharmacotherapies for defective ABC transporters.针对缺陷型ABC转运蛋白的靶向药物疗法。
Biochem Pharmacol. 2017 Jul 15;136:1-11. doi: 10.1016/j.bcp.2017.02.020. Epub 2017 Feb 27.
Zotero 插件